Clear cell carcinoma is a category of cancer defined by how the tumor cells look under a microscope: their interiors appear pale or empty, as though the cytoplasm has been washed away. That washed-out look comes from an abnormal buildup of glycogen, lipids, or mucin inside the cells, which dissolves during standard tissue processing and leaves behind a glassy blank space.1ScienceDirect (Diagnostic Histopathology). Malignant cutaneous clear cell tumours: a review of histological, immunohistochemical and molecular features The term covers cancers arising in several different organs, most commonly the kidney, ovary, and uterus, each with its own biology, risk profile, and treatment landscape. Despite sharing a name, these cancers behave quite differently depending on where they start.
Why the Cells Look “Clear”
The hallmark appearance is not a type of cell but a consequence of what is going on inside it. In renal (kidney) clear cell carcinoma, the dominant mechanism involves a faulty oxygen-sensing pathway that tricks cells into stockpiling fat. When the VHL gene is lost or mutated, a protein called HIF (hypoxia-inducible factor) stays active even in the presence of normal oxygen levels. One downstream effect is that HIF suppresses an enzyme called CPT1A, which normally shuttles fatty acids into mitochondria for burning as fuel. With CPT1A turned down, fatty acids get rerouted into lipid droplets instead, ballooning the cell with stored fat.2Nature Communications. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism When the tissue is processed for a biopsy slide, those lipids wash out, and the pathologist sees the characteristic clear windows.
In ovarian and uterine clear cell carcinomas, glycogen accumulation plays a bigger role than lipid. Under the microscope, these tumors often show distinctive “hobnail” cells, where the nucleus bulges out from the cell surface like a nail head, arranged in solid, papillary, or tube-like patterns.3PubMed Central. Clear Cell Carcinoma of the Endometrium Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases The visual outcome is similar, but the underlying metabolic disruption differs from the kidney version.
Where Clear Cell Carcinoma Occurs
The kidney is by far the most common site. Clear cell renal cell carcinoma (ccRCC) accounts for roughly 70 to 80 percent of all kidney cancers. It tends to be highly vascular, meaning it builds an extensive blood-vessel network to feed itself, which is both a vulnerability that drugs can exploit and a reason it can bleed or spread aggressively.
Ovarian clear cell carcinoma (OCCC) makes up a smaller share of ovarian cancers overall but is disproportionately common in East Asian populations, where it can represent a quarter or more of ovarian malignancies. It is strongly linked to endometriosis, a condition where tissue resembling the uterine lining grows outside the uterus. Endometriosis acts as an estrogen-dependent precursor that can, over time, give rise to clear cell or endometrioid ovarian cancer.4PubMed Central. Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity?
Clear cell carcinoma of the uterus (endometrium or cervix) is rarer. In a national French study of uterine clear cell carcinoma, the median age at diagnosis was about 69, most tumors were caught at an early stage, and hormone receptor expression was very low, with only about 13 percent of tumors testing positive for estrogen receptors.5PubMed Central. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network That low hormone sensitivity matters because it means these tumors don’t respond to hormone therapy the way some other uterine cancers do.
Even rarer sites exist. A type called hyalinizing clear cell carcinoma can appear in the salivary glands and, very occasionally, in the lung, where it makes up less than 0.1 percent of primary lung tumors. These are typically slow-growing, with low cell-division rates, and are more common in women and nonsmokers.6PubMed Central. Pulmonary salivary gland tumor–hyalinizing clear cell carcinoma: a literature review
Causes and Risk Factors
The risk factors depend heavily on which organ is involved. For clear cell renal cell carcinoma, the best-established risks are cigarette smoking, obesity, and high blood pressure.7PubMed Central. Renal cell carcinoma: links and risks Chronic kidney disease is also a recognized contributor.8PubMed Central. Epidemiology and Risk Factors for Kidney Cancer These are modifiable risks, which means quitting smoking and managing weight and blood pressure are meaningful prevention strategies.
For ovarian clear cell carcinoma, endometriosis is the standout risk factor. The chronic inflammation and hormonal environment of endometriotic cysts appear to create a setting where mutations can accumulate and a tumor can take root. Women with endometriosis don’t inevitably develop cancer, but the association is strong enough that ongoing monitoring is recommended.
Hereditary syndromes account for a small but important fraction of kidney clear cell cases. Von Hippel-Lindau (VHL) disease is the classic example. People with an inherited loss-of-function mutation in the VHL gene are predisposed to ccRCC, often developing tumors in both kidneys and at younger ages than typical. In a cohort study of VHL families in Nova Scotia, about a third of patients developed renal cell carcinoma, and most of those tumors were bilateral.9PubMed Central. Hereditary renal cell carcinoma associated with von Hippel-Lindau disease: a description of a Nova Scotia cohort VHL disease also causes tumors in the brain, spinal cord, eyes, and adrenal glands, so screening programs for affected families cover multiple organs.
Key Genetic Drivers
The molecular story differs strikingly between kidney and ovarian forms. In the kidney, the VHL-HIF axis is the central event. When both copies of the VHL gene are knocked out, the cell loses its ability to degrade HIF proteins under normal oxygen conditions. HIF accumulates and switches on genes that promote blood vessel growth, cell survival, and the lipid storage that gives the cells their clear look. This understanding has been the foundation for nearly every targeted drug developed for ccRCC over the past two decades.
In ovarian clear cell carcinoma, the dominant genetic event is different: mutations in a gene called ARID1A, which helps remodel chromatin, the structural packaging around DNA. Two independent studies found ARID1A mutations in roughly half of all ovarian clear cell carcinomas tested. One study found mutations in 57 percent of cases and also identified PPP2R1A mutations in about 7 percent.10PubMed Central. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma The other study found ARID1A mutations in 46 percent of ovarian clear cell carcinomas and 30 percent of endometrioid carcinomas, but in none of the high-grade serous ovarian cancers tested, highlighting how specific this mutation is to the clear cell subtype.11PubMed Central. ARID1A mutations in endometriosis-associated ovarian carcinomas
Uterine clear cell carcinomas carry yet another molecular profile. In the French national cohort, alterations in the PI3K signaling pathway were common: about 58 percent showed loss of PTEN and half had PIK3CA mutations. Abnormalities in the P53 tumor suppressor were seen in 41 percent, and about one in five tumors had mismatch repair deficiency, a feature that can make them eligible for immunotherapy.5PubMed Central. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network These differences across organ sites are why “clear cell carcinoma” is not a single disease with one treatment playbook.
How It Is Diagnosed
Diagnosis starts with imaging and ends with a biopsy. For kidney tumors, CT scanning is typically the first-line tool for staging and surgical planning because it shows tumor size, blood supply, and whether cancer has spread. MRI adds value when more detail is needed on the tumor’s tissue composition and subtype characteristics.12Journal of Clinical Imaging Science. Computed tomography and magnetic resonance imaging characteristics of renal cell carcinoma: Differences between subtypes and clinical evaluation The different kidney cancer subtypes often show distinct patterns on imaging: clear cell tumors tend to enhance intensely with contrast due to their dense blood-vessel networks, while papillary tumors enhance less.13PubMed Central. Review of renal cell carcinoma and its common subtypes in radiology
Under the microscope, pathologists use a panel of protein markers to distinguish clear cell RCC from look-alike subtypes. Clear cell renal tumors typically stain positive for a marker called CA IX and negative for CK7 and AMACR, a pattern that separates them from papillary RCC and from rarer translocation-driven tumors.14PubMed Central. Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features For gynecologic clear cell carcinomas, the marker Napsin A is particularly useful. In one study of cervical tumors, Napsin A was positive in about 79 percent of clear cell carcinomas but only 17 percent of a mimicking subtype called gastric-type adenocarcinoma, making it a reliable way to tell the two apart.15PubMed. Expression of Markers of MĂĽllerian Clear Cell Carcinoma in Primary Cervical and Vaginal Gastric-type Adenocarcinomas
Artificial intelligence is beginning to enter this space. A recent study tested a self-attention-based deep learning model on CT images and found it could distinguish clear cell RCC from other kidney tumors with about 82 percent accuracy and an area under the curve of 0.91, outperforming older neural network architectures.16PubMed. Performance of a self-attention-based model in the task of differentiating clear cell renal cell carcinoma from other renal tumors: variable Vision Transformer These tools aren’t replacing pathologists yet, but they’re edging toward clinical usefulness as second-opinion screening aids.
Treatment of Clear Cell Renal Cell Carcinoma
Surgery remains the foundation when the tumor is confined to the kidney. For localized disease, removing part or all of the kidney can be curative. The treatment landscape gets more complex once the cancer has spread, and this is where the molecular understanding of the VHL-HIF pathway has paid off.
The first generation of targeted therapies for advanced ccRCC blocked vascular endothelial growth factor (VEGF), the protein HIF drives up to feed new blood vessel growth. Drugs like sunitinib and pazopanib became standard options. In a pivotal trial, pazopanib roughly doubled progression-free survival compared to placebo in patients with metastatic disease.17PubMed Central. Update on Targeted Therapies for Clear Cell Renal Cell Carcinoma
Immunotherapy has since changed the field. A landmark trial comparing the combination of nivolumab plus ipilimumab against sunitinib in patients with intermediate- or poor-risk advanced kidney cancer found that the immunotherapy combination substantially improved survival. The 18-month overall survival rate was 75 percent with the combination versus 60 percent with sunitinib, and the complete response rate was 9 percent compared to just 1 percent.18PubMed. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Combinations of immunotherapy with VEGF-targeted drugs have become the backbone of first-line treatment for most patients with advanced ccRCC.
When patients progress after immunotherapy, VEGF-targeted drugs still have a role. A systematic review found consistent evidence that anti-VEGF treatments remain active after prior checkpoint-inhibitor therapy, with no new safety signals and no increase in immune-related side effects from the earlier treatment.19Cancer Treatment Reviews. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review
Why Tumor Genetics Shape Drug Response
Not all clear cell kidney tumors respond equally to the same therapy, and genomic profiling is starting to explain why. Two genes mutated in ccRCC alongside VHL, called PBRM1 and BAP1, appear to pull treatment responses in opposite directions. In one study, patients with PBRM1 mutations stayed on VEGF-targeted therapy for a median of 12 months before the treatment stopped working, compared to about 7 months for patients without those mutations. BAP1 mutations showed the reverse pattern: patients with BAP1 mutations had a shorter time on therapy (about 6 months) compared to those without them (about 11 months).20PubMed Central. Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma
Resistance to immunotherapy is also an active area of investigation. Researchers have identified a protein called TUBA1C that appears to be elevated in ccRCC cells after checkpoint-inhibitor treatment and is correlated with resistance. Patients with high expression of this protein also tend to carry a greater burden of genetic mutations overall, which is linked to worse outcomes.21PubMed Central. TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma Understanding these resistance mechanisms is critical because even the best current therapies eventually stop working in most patients with metastatic disease.
The Chemoresistance Problem in Ovarian Clear Cell Carcinoma
Ovarian clear cell carcinoma occupies an uncomfortable position in gynecologic oncology: it is one of the subtypes least responsive to platinum-based chemotherapy, which remains the workhorse for most other ovarian cancers. Several mechanisms have been proposed, including increased drug detoxification and enhanced DNA repair, but the most compelling explanation may be the simplest one. These tumors grow slowly. Their cell-division rate, measured by a marker called Ki-67, is significantly lower than in serous ovarian cancers. Because platinum drugs work by damaging DNA during cell division, cells that divide less frequently are harder to kill. Studies have confirmed that patients whose tumors had higher Ki-67 levels responded better to chemotherapy, regardless of tumor type.22PubMed Central. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma
Epigenetic changes add another layer. One study found that lower methylation of a specific genetic element, HERV-K, was associated with platinum resistance in ovarian clear cell carcinoma.23PubMed. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance These findings are still being translated into clinical tools, but they point toward a future where molecular profiling could help identify which patients with OCCC are unlikely to benefit from conventional chemo and should move directly to other approaches.
Prognosis Depends Heavily on Stage
When caught early, ovarian clear cell carcinoma has surprisingly good outcomes. In a Memorial Sloan Kettering study, the three-year overall survival rate for patients with stage I disease was about 90 percent. Even within stage I, though, the details matter: patients with tumors confined inside an intact ovarian capsule (stage IA) had a three-year survival of about 94 percent, while those whose tumors involved the ovarian surface had a rate closer to 72 percent.24PubMed Central. Ovarian Clear Cell Carcinoma, Outcomes by Stage: The MSK Experience
Advanced-stage disease tells a starkly different story. Three-year overall survival dropped to about 53 percent for stage III and roughly 30 percent for stage IV in the same study.24PubMed Central. Ovarian Clear Cell Carcinoma, Outcomes by Stage: The MSK Experience The gap between early and late stage is wider in clear cell carcinoma than in some other ovarian subtypes, partly because the chemoresistance discussed earlier means that advanced tumors are harder to control once surgery alone can’t remove everything.
For kidney clear cell carcinoma, the stage-dependent pattern is similar. Localized tumors treated with surgery have high cure rates, while metastatic ccRCC, though more treatable than it was a decade ago thanks to immunotherapy combinations, remains a disease that is managed rather than cured in most cases.
Emerging Therapies and New Directions
One of the most exciting recent advances is belzutifan, a drug that directly blocks HIF-2α. Rather than attacking the blood vessels HIF creates, belzutifan goes after the oxygen-sensing protein itself. It was initially approved for tumors associated with inherited VHL disease, but case reports have shown responses even in patients with somatic (non-inherited) VHL mutations, including patients in acute crisis with rapidly progressing disease.25PubMed Central. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation Trials combining belzutifan with immunotherapy or other targeted agents are ongoing.
Neoadjuvant therapy, giving drugs before surgery to shrink the tumor, is also being explored. A phase II trial testing the combination of sitravatinib (a multi-kinase inhibitor) with nivolumab before kidney removal showed that the regimen was safe, with no grade 4 or 5 treatment-related adverse events, and that the tumor microenvironment became more immunologically active by the time of surgery.26Nature Communications. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma The idea is that priming the immune system before removing the main tumor could mop up microscopic disease left behind and reduce recurrence.
Cell therapy is entering early trials as well. ALLO-316, an off-the-shelf CAR-T cell product targeting a protein expressed on ccRCC cells, has shown preliminary activity in a phase 1 study. The side-effect profile was significant, with about 84 percent of patients experiencing grade 3 or higher adverse events and cytokine release syndrome occurring in over half of treated patients, though severe cases were uncommon.27Journal of Clinical Oncology. ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study Whether this approach will eventually find a niche in heavily pretreated patients remains to be seen, but the fact that cell therapy is even being attempted for a solid tumor like ccRCC signals how much the treatment landscape is expanding.
Managing Side Effects of Targeted Therapy
Living on targeted therapy or immunotherapy for months or years means dealing with side effects that accumulate in ways traditional short-course chemotherapy does not. VEGF-targeted drugs commonly cause fatigue, high blood pressure, hand-foot skin reactions, and diarrhea. Immunotherapy combinations can trigger autoimmune-type inflammation in almost any organ. The good news is that the majority of these side effects, at least in clinical trial settings, are mild to moderate and can be managed with dose adjustments, supportive medications, and close monitoring.28PubMed Central. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies
Early detection of side effects makes a real difference. For drugs like sunitinib, guidelines recommend checking in after the first couple of treatment cycles to assess fatigue and its impact on daily life. If quality of life is suffering and simpler measures haven’t helped, reducing the dose is preferred over discontinuing a drug that is otherwise working against the cancer.29JNCI: Journal of the National Cancer Institute. Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies The overall goal is to keep patients on effective treatment for as long as possible while maintaining a reasonable quality of life, a balance that requires active communication between patients and their oncology teams.